CCTG MA.39: Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer
Enrolling By Invitation
35 years and older
Female
Phase
N/A
Brief description of study
This study will compare the good and bad effects of not giving regional radiotherapy versus using regional radiotherapy in patients with low risk breast cancer as indicated by Oncotype DX Recurrence Score. This is intended to help researchers discover if not giving regional radiotherapy will be as beneficial as using regional radiotherapy. In this approach, not giving radiotherapy should keep breast cancer from coming back in patients as good as giving regional radiotherapy would.
Detailed description of study
This study is currently Enrolling by Invitation at Lancaster General Hospital - ABBCI.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: regional radiotherapy, biomarker low risk node and T3N0 Positive Breast Cancer
-
Age: 35 Years
-
Gender: Female
Inclusion Criteria:
- Newly diagnosed histologically proven invasive carcinoma of the breast with no evidence of metastases
- Treated with breast conserving surgery or mastectomy
- May not have had adjuvant chemotherapy
Exclusion Criteria:
- Patients with nodal disease
- Any prior history of chestwall/thoracic radiation
- Patients who are pregnant
Updated on
01 Aug 2024.
Study ID: CCTG MA.39
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
